Wolverine Stack
Also called wolverine, BPC and TB
The Wolverine Stack is the famous recovery duo - BPC-157 and TB-500 in one vial - named for the healing factor everyone wishes they had.
No trial has studied this one. Everything below comes from community-reported dosing and results — what people actually run, and what they report happening.
BPC-157 + TB-500
Each of those has its own record. The combination itself has not been studied as a combination — what is known is known about the parts.
- Recovery & injury
The quick answer
The Wolverine Stack is the famous recovery duo - BPC-157 and TB-500 in one vial - named for the healing factor everyone wishes they had. The two work as a team: BPC-157 drives the local repair right at the injury, while TB-500 helps cells migrate and gets the whole body's repair response moving.
Because these are repair peptides, there's no acute "feel" - people report less soft-tissue and joint discomfort and faster recovery over two to four weeks, with fuller results across a couple of months. Honest note: there's essentially no long-term human safety data for either, and both encourage new blood-vessel growth, which is worth keeping in mind for anyone with an undiagnosed cancer.
What it is not
No study has ever looked at this combination. The grade reflects the blend, not its components.
Why people use it
🐺 Heal like Wolverine; 🦵 Repairs tendons, ligaments and muscle; 🏃 Faster bounce-back from injury; 🔧 Local plus whole-body repair; ⏱️ Less downtime
What people report using
These are ranges other people have reported running. They are here so you can see what has actually been done — they are not medical advice and not a recommendation for you.
People report running this anywhere from 0.6mg to 1mg, every day, near the injury.Where somebody sits in that range depends on what they are using it for and what they are starting from — the low end is a deliberate choice a lot of people make, not a half-hearted version of the high end.
Recovery & injury
- How often
- Every day, near the injury
- Route
- subcutaneous
- Where this comes from
- Animal and lab research
BPC-157 and TB-500 together.
Recovery & injury
- How often
- Every day, near the injury
- Route
- subcutaneous
- Where this comes from
- Animal and lab research
BPC-157 and TB-500 together.
20mg vial + 2ml BAC water = 10mg/ml. 0.6mg = 6u, 0.8mg = 8u, 1mg = 10u. Daily, under the skin near the injury site.
Work out your own units on the reconstitution calculator — the most common serious mistake in this area is arithmetic, not chemistry.
What to expect, and when
- First thing people notice
- Days 3–7 (pain reduction)
- When it gets real
- Weeks 1–2 (inflammation)
- Where it peaks
- Weeks 4–8 (structural repair)
- Patience needed
- Medium - injury dependent
- Days 1–3Both peptides loading
The idea behind pairing these is complementary mechanisms: BPC-157 is studied for local repair and angiogenesis, while TB-500 (a thymosin β4 fragment) binds G-actin to mobilize cell migration. Early on this is groundwork, not felt effect. Users rarely report much in the first few days. Research context only - clinics pair them anecdotally, not from large trials.
- Days 3–7Early pain reduction
Users most often report the first drop in pain or stiffness here, an effect usually attributed to the BPC-157 side, which tends to act faster. Preclinical thymosin β4 data show reduced inflammatory signaling during the repair phase. Expect a softening of symptoms rather than resolution. Keep framing preliminary - human trials of the combination are essentially absent.
- Weeks 1–2Inflammation and mobility improve
Reviews describe TB-500's contribution as slower than BPC-157's: reduced inflammation and improved mobility in an injured area commonly emerge across weeks 1–2. Rat wound models show reepithelialization gains for thymosin β4. Users often notice easier movement before they notice true load tolerance. Progress is real but incremental.
- Weeks 2–4Migration and remodeling
This window is where the migration-plus-local-repair rationale is thought to compound: repair cells recruited to the site plus an improved local repair environment. Preclinical evidence suggests better collagen deposition and angiogenesis. Users frequently report recovering faster between training or aggravations. Individual variation is large and injury-dependent.
- Weeks 4–8Structural repair peak
Load-tolerance improvements and the most convincing structural gains are commonly reported across weeks 5–8, matching the slower TB-500 timeline. In a research context this reflects tissue-level remodeling rather than symptom masking. Outcomes vary considerably between individuals and by injury type. Neither peptide is an approved drug - this is educational context, not a protocol.
The combination has no meaningful human clinical trial evidence; timelines blend animal data with user-reported patterns and vary heavily by injury.
Side effects, and what people do about them
BPC-157 and TB-500 together - a favourite for recovery and generally very easy to tolerate. A little nausea, a head-rush, or site tenderness is about all anyone usually notices, sometimes with a bit of tiredness as repair ramps up. As with any newer peptide, check with your doctor first if you have ongoing health concerns.
Go deeper
Open these only if you want them.
How it actually works
BPC-157 with TB-500, per this row's own evidence caveat - two repair signals that work on genuinely different parts of the problem. BPC-157 acts on the blood-supply side, upregulating VEGFR2 signalling and nitric-oxide pathways to drive angiogenesis and fibroblast migration. TB-500, a fragment of thymosin beta-4, sequesters actin monomers and so governs cytoskeletal reorganisation and cell migration.
That complementarity is the mechanistic case for the pairing and it is a reasonable one. It is not evidence: no study has examined the combination, which is why the grade is capped at community convention regardless of what is known about either component alone.
What people report, in full
The BPC-157 + TB-500 combo is a staple in the sports-medicine crowd, and the synergy story is compelling even if it isn't formally proven. About 75-80% report less pain and better mobility by week four, with deeper healing over weeks four to eight; the rest see little, usually depending on the injury type and how close to the injury they inject. Local injection at the injury site is the common recommendation, and people often add topical GHK-Cu alongside it.
On amounts, reported practice lands at roughly half a milligram to a milligram of total blend per day - about 0.25 to 0.5mg of each component. Our 0.6mg daily sits squarely inside that. One figure worth flagging because it circulates widely and is wrong: five milligrams of each compound daily, ten milligrams a day in total. That is a vial's contents mistaken for a single dose, and it is compounded by TB-500's weekly loading amount being read as a daily one. Ten milligrams a day would empty a 20mg vial in two days.
Worth knowing
This is the normal state of this category and it is not a black mark. It usually means nobody could patent the molecule tightly enough to fund a trial. It is not the same as having been tested and failed.
Sources and review
This record is built on what the wider community reports doing and experiencing, summarised above. No counted dataset has been attached to this compound yet — when one is published, it goes here with its numbers.
People also look at
Still not sure?
Ask it the way you would ask a person. Follow-up questions are the point — it remembers what you already said.
Ask about Wolverine Stack